Malignant Pleural Mesothelioma: Current Challenges and Future Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 4961

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
Interests: lung cancer; malignant mesothelioma; chemotherapy; immunotherapy; asbestos-related diseases
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Respiratory Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
Interests: ung cancer; malignant mesothelioma; chemotherapy; immunotherapy; asbestos-related diseases

Special Issue Information

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that develops in the mesothelial cell layer of the pleura. Exposure to asbestos is a well-known cause of MPM. The global incidence of MPM has continuously risen along with widespread industrial use of asbestos. Recent reports have demonstrated that mesothelioma patients with familial aggregation are associated with BAP1 mutation. Recent progress in basic research and clinical practice has demonstrated some crucial evidence relating to molecular pathogenesis and perspectives on potential therapeutic approaches leading to promising treatment.

This issue is designed to provide a state-of-the-art overview of recent scientific research on mesothelioma, including pathogenesis, diagnosis, and management of MPM.

This Issue will identify the unmet needs in the diagnosis and management of MPM based on a combination of original research and review papers.

Topics will include:

  • The pathogenesis of MPM;
  • The challenge in the diagnosis of MPM;
  • The role of surgery in the treatment of MPM;
  • The paradigm shift of systemic therapy of MPM;
  • Supportive care in MPM.

Prof. Dr. Nobukazu Fujimoto
Prof. Dr. Kozo Kuribayashi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asbestos
  • BAP-1
  • CTLA-4
  • immunotherapy
  • mesothelioma
  • PD-1

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 575 KiB  
Article
Depression and Complicated Grief, and Associated Factors, of Bereaved Family Members of Patients Who Died of Malignant Pleural Mesothelioma in Japan
by Yasuko Nagamatsu, Yumi Sakyo, Edward Barroga, Riwa Koni, Yuji Natori and Mitsunori Miyashita
J. Clin. Med. 2022, 11(12), 3380; https://doi.org/10.3390/jcm11123380 - 13 Jun 2022
Cited by 2 | Viewed by 1530
Abstract
Objectives: we investigated the prevalence and associated factors of depression and complicated grief (CG) among bereaved family members of malignant pleural mesothelioma (MPM) patients in Japan. Methods: Bereaved family members of MPM patients (n = 72) were surveyed. The Japanese version of [...] Read more.
Objectives: we investigated the prevalence and associated factors of depression and complicated grief (CG) among bereaved family members of malignant pleural mesothelioma (MPM) patients in Japan. Methods: Bereaved family members of MPM patients (n = 72) were surveyed. The Japanese version of the Patient Health Questionnaire-9 (PHQ-9) and the Japanese version of the Brief Grief Questionnaire (BGQ) were used to assess depression and complicated grief (CG), respectively. Socio-economic factors, anger toward asbestos, care satisfaction, achievement of good death, and quality of end-of-life care were assessed in relation to depression and CG. Results: In the family members of MPM patients, the frequencies of depression and CG were 19.4% and 15.3%, respectively. The bereaved family members who were not compensated by the asbestos-related health-damage relief system (p = 0.018) and who felt the financial impacts of the patient’s MPM on the family (p = 0.006) had a higher likelihood of depression. The bereaved family members who were not satisfied with the care given when the patient became critical (p = 0.034), who were not compensated by the asbestos-related health-damage relief system (p = 0.020), who felt the financial impact of the patient’s MPM on the family (p = 0.016), and whose deceased relative underwent surgery (p = 0.030) had a higher likelihood of CG. Conclusions: For bereaved family members of MPM patients, routine screening for depression and CG and the provision of grief care are suggested. In addition, for family members of MPM patients, financial support, including the promotion of the asbestos-related health-damage relief system, and improved care for patients who undergo surgery and when patients become critical, are recommended. Full article
Show Figures

Graphical abstract

12 pages, 1472 KiB  
Article
Bereaved Family Members’ Perspectives of Good Death and Quality of End-of-Life Care for Malignant Pleural Mesothelioma Patients: A Cross-Sectional Study
by Yasuko Nagamatsu, Yumi Sakyo, Edward Barroga, Riwa Koni, Yuji Natori and Mitsunori Miyashita
J. Clin. Med. 2022, 11(9), 2541; https://doi.org/10.3390/jcm11092541 - 1 May 2022
Cited by 1 | Viewed by 1446
Abstract
Objective: This study investigated whether malignant pleural mesothelioma (MPM) patients achieved good deaths and good quality of end-of-life care compared with other cancer patients from the perspective of bereaved family members in Japan. Methods: This cross-sectional study was part of a larger study [...] Read more.
Objective: This study investigated whether malignant pleural mesothelioma (MPM) patients achieved good deaths and good quality of end-of-life care compared with other cancer patients from the perspective of bereaved family members in Japan. Methods: This cross-sectional study was part of a larger study on the achievement of good deaths of MPM patients and the bereavement of their family members. Bereaved family members of MPM patients in Japan (n = 72) were surveyed. The Good Death Inventory (GDI) was used to assess the achievement of good death. The short version of the Care Evaluation Scale (CES) version 2 was used to assess the quality of end-of-life care. The GDI and CES scores of MPM patients were compared with those of a Japanese cancer population from a previous study. Results: MPM patients failed to achieve good deaths. Only 12.5% of the MPM patients were free from physical pain. The GDI scores of most of the MPM patients were significantly lower than those of the Japanese cancer population. The CES scores indicated a significantly poorer quality of end-of-life care for the MPM patients than the Japanese cancer population. The total GDI and CES scores were correlated (r = 0.55). Conclusions: The quality of end-of-life care for MPM patients remains poor. Moreover, MPM patients do not achieve good deaths from the perspective of their bereaved family members. Full article
Show Figures

Graphical abstract

Other

Jump to: Research

8 pages, 429 KiB  
Systematic Review
Second Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review
by Alice Bellini, Sara Mazzarra, Sara Sterrantino, Desideria Argnani and Franco Stella
J. Clin. Med. 2022, 11(12), 3340; https://doi.org/10.3390/jcm11123340 - 10 Jun 2022
Cited by 2 | Viewed by 1303
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumour with poor prognosis. To date, a multimodality treatment, including chemotherapy and surgery, with or without radiotherapy, is the gold standard therapy for selected patients with epithelioid and early-stage MPM. In this setting, the goal [...] Read more.
Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumour with poor prognosis. To date, a multimodality treatment, including chemotherapy and surgery, with or without radiotherapy, is the gold standard therapy for selected patients with epithelioid and early-stage MPM. In this setting, the goal of surgery is to achieve the macroscopic complete resection, obtained by either extrapleural pneumonectomy or pleurectomy/decortication. Failure, in local and/or distant sites, is one of the major concerns; in fact, there has been no established treatment for the recurrence of MPM after the multimodal approach, and the role of surgery in this context is still controversial. By using electronic databases, studies that included recurrent MPM patients who underwent a second surgery were identified. The endpoints included were: a pattern of recurrence, post-recurrence survival (PRS), and the type of second surgery. When available, factors predicting better PRS and perioperative mortality and morbidity were collected. This systematic review offers an overview of the results that are currently obtained in patients undergoing a second surgery for relapsed MPM, with the aim to provide a comprehensive view on this subject that explores if a second surgery leads to an improvement in survival. Full article
Show Figures

Figure 1

Back to TopTop